Nov 22 (Reuters) - Halozyme Therapeutics Inc HALO.O:
HALOZYME WITHDRAWS PROPOSAL TO ACQUIRE EVOTEC FOLLOWING EVOTEC'S UNWILLINGNESS TO ENGAGE IN DISCUSSIONS
REITERATE RAISED 2024 GUIDANCE FOR REVENUE OF $970-$1,020 MILLION AND ADJUSTED EBITDA OF $595-$625 MILLION
TO DATE, EVOTEC HAS BEEN UNWILLING TO ENGAGE WITH US TO EXPLORE A POTENTIAL COMBINATION AND A COMPANY SPOKESPERSON HAS PUBLICLY COMMENTED THAT ITS GOAL IS TO REMAIN AN INDEPENDENT COMPANY
Source text: ID:nPn4cwbXMa
Further company coverage: EVTG.DE
(Gdansk Newsroom)
(((( gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。